Pharmacytimes: Condition Center: Heart Failure http://www.pharmacytimes.com/condition-resources/heart-failure/condition-rss Heart Failure en-us Tue, 23 May 2017 06:33:09 UTC Tue, 23 May 2017 06:33:09 UTC Stem Cell Therapy for Heart Failure? Ixmyelocel-T to Prevent CV Events http://www.pharmacytimes.com/contributor/adam-remick/2017/05/stem-cell-therapy-for-heart-failure-ixmyelocel-t-to-prevent-cv-events 12:56 AM, Thu May 18, 2017 Pharmacists and Heart Failure: Room for Intervention in Every Practice Setting http://www.pharmacytimes.com/resource-centers/heart-failure/pharmacists-and-heart-failure-room-for-intervention-in-every-practice-setting Heat failure (HF) caused 1 in 9 deaths in the United States in 2009.&nbsp; 1:26 PM, Tue March 28, 2017 FDA Accepts NDA for Investigational Hypertension Drug http://www.pharmacytimes.com/product-news/fda-accepts-nda-for-investigational-hypertension-drug The FDA has accepted&nbsp;the new drug application (NDA) for EZR-201, an investigational product from Ezra Innovations for the treatment of hypertension and heart failure.&nbsp; 10:23 AM, Fri January 20, 2017 Heart Failure Risk Reduction Strategies and Transition of Care http://www.pharmacytimes.com/resource-centers/heart-failure/heart-failure-risk-reduction-strategies-and-transition-of-care-introduction In this clip, Dr. Peter Salgo,<strong> </strong>a professor of medicine and anesthesiology at Columbia University College of Physicians and Surgeons; and an associate director of Surgical Intensive Care at New York-Presbyterian Hospital discusses heart failure.&nbsp; 4:17 PM, Thu December 29, 2016 Flashcards and QR Codes Improve Medication Adherence in Patients with Diabetes, Hypertension, and Heart Failure http://www.pharmacytimes.com/resource-centers/diabetes/flashcards-and-qr-codes-improve-medication-adherence-in-patients-with-diabetes-hypertension-and-heart-failure Poor medication adherence contributes to 125,000 deaths annually, causes up to half of all treatment failures, and costs the US healthcare system $100 billion each year. 9:00 AM, Tue November 15, 2016 Heart Failure Treatment Strategies for Patients with Diabetes http://www.pharmacytimes.com/resource-centers/diabetes/heart-failure-treatment-strategies-for-patients-with-diabetes The incidence of heart failure is increasing as the world’s population ages and the rates of other, often comorbid, diseases (eg, diabetes, heart disease, obesity) increase. 8:00 AM, Tue October 25, 2016 Is It Time to Move On From Tolvaptan for Acute Heart Failure? http://www.pharmacytimes.com/contributor/douglas-jennings-pharmd-fccp-faha/2016/09/is-it-time-to-move-on-from-tolvaptan-for-acute-heart-failure This article summarizes recent literature surrounding the use of tolvaptan for acute heart failure. 4:30 AM, Wed September 28, 2016 Are ACE Inhibitors Interchangeable? http://www.pharmacytimes.com/contributor/thomas-szymanski-pharmd-candidate-2017/2016/09/are-ace-inhibitors-interchangeable That is, are they all equally effective? 10:04 PM, Mon September 19, 2016 Could CoQ10 Benefit Heart Failure Patients? http://www.pharmacytimes.com/resource-centers/heart-failure/could-coq10-benefit-heart-failure-patients Supplemental coenzyme Q10 may be a management option for patients with heart failure. 8:57 AM, Tue August 9, 2016 FDA Approves First Lisinopril Oral Solution http://www.pharmacytimes.com/product-news/fda-approves-first-lisinopril-oral-solution The FDA has approved Silvergate Pharmaceuticals’ Qbrelis, the first lisinopril oral solution. 8:00 AM, Fri August 5, 2016 Heart Failure Therapy: The Good, the Bad, and the Ugly http://www.pharmacytimes.com/contributor/douglas-jennings-pharmd-fccp-faha/2016/08/heart-failure-therapy-the-good-the-bad-and-the-ugly This article highlights the latest literature surrounding both new and old heart failure therapies. 9:52 PM, Tue August 2, 2016 Common Medications Can Trigger Heart Failure http://www.pharmacytimes.com/resource-centers/heart-failure/common-medications-can-trigger-heart-failure The American Heart Association has released a scientific statement cautioning against the use of some common drugs and supplements in patients with heart failure. 10:04 PM, Sun July 17, 2016 Should SSRIs Be Prescribed for Depression in Heart Failure Patients? http://www.pharmacytimes.com/contributor/douglas-jennings-pharmd-fccp-faha/2016/07/should-ssris-be-prescribed-for-depression-in-heart-failure-patients Depression affects 10% to 40% of patients with heart failure, depending on disease severity. 8:38 AM, Fri July 8, 2016 Why Entresto Is a Winner for Heart Failure http://www.pharmacytimes.com/contributor/mel-seabright-pharmd-mba/2016/07/why-entresto-is-a-winner-for-heart-failure Two new analyses have further cemented Entresto’s place in heart failure therapy. 10:24 PM, Mon July 4, 2016 Can Vitamin D Supplementation Benefit Heart Failure Patients? http://www.pharmacytimes.com/contributor/douglas-jennings-pharmd-fccp-faha/2016/06/can-vitamin-d-supplementation-benefit-heart-failure-patients This article explores recent evidence describing the potential benefits of vitamin D supplementation in patients with heart failure and reduced ejection fraction. 11:44 PM, Sun June 5, 2016 Heart Failure Guideline Update Puts Trust in Entresto http://www.pharmacytimes.com/contributor/imran-chughtai-pharmd/2016/06/heart-failure-guideline-update-puts-trust-in-entresto The American College of Cardiology, American Heart Association, and Heart Failure Society of America recently updated guidelines for pharmacological heart failure treatment, focusing specifically on 2 new agents. 9:44 PM, Wed June 1, 2016 Updated Heart Failure Guidelines Highlight Role of Entresto, Corlanor http://www.pharmacytimes.com/resource-centers/heart-failure/updated-heart-failure-guidelines-highlight-role-of-entresto-corlanor The American College of Cardiology, the American Heart Association, and the Heart Failure Society of America have updated heart failure guidelines to recommend the use of 2 medications: sacubitril/valsartan (Entresto) and ivabradine (Corlanor). 1:00 AM, Tue May 24, 2016 New Heart Failure Guidelines: What Pharmacists Need to Know http://www.pharmacytimes.com/contributor/douglas-jennings-pharmd-fccp-faha/2016/05/new-heart-failure-guidelines-what-pharmacists-need-to-know This article highlights the latest evidence from both the AHA/ACC and ESC guidelines, which were both published this past weekend. 9:10 PM, Sun May 22, 2016 Entresto Shows Benefit Even in Clinically Stable Heart Failure Patients http://www.pharmacytimes.com/resource-centers/heart-failure/entresto-shows-benefit-even-in-clinically-stable-heart-failure-patients Novartis’ sacubitril/valsartan (Entresto) is showing promise for heart failure patients with reduced ejection fraction, regardless of background therapy or clinical stability. 7:00 AM, Thu April 14, 2016 ENTRESTO™ (sacubitril/valsartan) for the Management of Heart Failure http://www.pharmacytimes.com/publications/issue/2016/March2016/r727_march2016 ENTRESTO™ (sacubitril/valsartan) tablets 24/26 mg, 49/51 mg, 97/103 mg, from Novartis Pharmaceuticals Corporation, are a combination of an angiotensin receptor blocker and a novel neprilysin inhibitor, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (New York Heart Association class II through IV) and reduced ejection fraction. 5:14 AM, Thu March 31, 2016